BEIJING, March 4 (Xinhua) -- Chinese scientists have identified a protein that causes the proliferation of liver cancer cells, a finding which could assist in the development of a new cancer drug, Monday's China Daily reported. By studying proteins of patients with early-stage liver cancer, r...
ONCONASE(ONC), A PROTEIN USED FOR THE THERAPY OF PATIENTS WITH ADVANCED PANCREATIC CANCER (PC): A PHASE I/II TRIAL.An abstract is unavailable. This article is available as a PDF only.doi:10.1097/00002371-199410000-00012Chun, H.Costanzi, J....
Determination of the predictors of hypoproteinemia among cancer patients following extensive surgery may enhance their nutritional management and clinical outcome. This study evaluated the predictive factors of postoperative hypoproteinemia among cancer patients following extensive abdominal surgery. An age- an...
Therefore, it is crucial to understand the molecular mechanisms underlying cancer for early diagnosis, as well as estimation of prognosis and determining the most suitable drug treatment for cancer patients. Genomics studies have progressed towards comprehensive molecular characterization of human cancers, ...
The drug is designed to treat patients with a form of acute myeloid leukemia in which the enzyme isocitrate dehydrogenase 1 (IDH1) is mutated, researchers at the University of Texas MD Anderson Cancer Center said. IDH1 mutations occur in 6 to 10 percent of AML patients. ...
Protein-protein interactions (PPIs) are central to a variety of biological processes, and their dysfunction is implicated in the pathogenesis of a range of human diseases, including cancer. Hence, the inhibition of PPIs has attracted significant attentio
et al. Personalized liposome–protein corona in the blood of breast, gastric and pancreatic cancer patients. Int. J. Biochem. Cell Biol. 75, 180–187 (2016). Article CAS Google Scholar Pink, M., Verma, N., Kersch, C. & Schmitz-Spanke, S. Identification and characterization of small ...
“We hope that further research will help translate these findings into targeted therapies for breast cancer patients.” Dr Simon Vincent, director of research, support and influencing at Breast Cancer Now, said: “It’s exciting that a variant of a previously overlooked ...
Molecularly targeted cancer therapies substantially improve patient outcomes, although the durability of their effectiveness can be limited. Resistance to these therapies is often related to adaptive changes in the target oncoprotein which reduce binding
"For patients with triple-negative breast cancer, systemic chemotherapies are largely ineffective and highly toxic," Yu said. "So nanoparticles are a promising approach for delivering more targeted treatments, such as OXO, to stop the deadly process of metastasis." ...